STOCK TITAN
  1. Home
  2. News
  3. WVE

Wave Life Sciences Ltd. - WVE STOCK NEWS

IMPACT
SENTIMENT
WVE : Nasdaq
Wave Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
conferences
IMPACT
SENTIMENT
WVE : Nasdaq
Wave Life Sciences to Highlight RNA Editing Modality and PRISM Platform Advancements During Upcoming Scientific Conferences
conferences
IMPACT
SENTIMENT
WVE : Nasdaq
Wave Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update
earnings
IMPACT
SENTIMENT
WVE : Nasdaq
Wave Life Sciences to Webcast Conference Call of Second Quarter 2021 Financial Results on August 5, 2021
conferences earnings
IMPACT
SENTIMENT
WVE : Nasdaq
Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a FOCUS-C9 Clinical Trial of WVE-004 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
clinical trial
IMPACT
SENTIMENT
WVE : Nasdaq
Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency
clinical trial
IMPACT
SENTIMENT
WVE : Nasdaq
Wave Life Sciences to Present at Jefferies Virtual Healthcare Conference
conferences
IMPACT
SENTIMENT
WVE : Nasdaq
Wave Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update
earnings
IMPACT
SENTIMENT
WVE : Nasdaq
Wave Life Sciences to Present at RBC Capital Markets Global Healthcare Virtual Conference
conferences
IMPACT
SENTIMENT
WVE : Nasdaq
Wave Life Sciences to Webcast Conference Call of First Quarter 2021 Financial Results on May 13, 2021
conferences earnings
Stock WVE logo
Wave Life Sciences Ltd.

Nasdaq:WVE

WVE Rankings

#3558 Ranked by Market Cap
#1217 Ranked by Stock Gains
N/A Ranked by Dividends

WVE Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Singapore
7 Straits View

About WVE

wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.